One of the most common hormonal conditions affecting women worldwide has been officially renamed, with polycystic ovary syndrome (PCOS) now known as polyendocrine metabolic ovarian syndrome (PMOS) — a change health experts say will improve diagnosis rates and open the door to more effective, targeted treatment.
Health authorities have approved a significant renaming of polycystic ovary syndrome (PCOS), now to be called polyendocrine metabolic ovarian syndrome (PMOS), in a move welcomed by clinicians and patient advocates who long argued the original name was misleading and harmful to those seeking a diagnosis.
The change, reported on 12 May 2026, addresses a core problem with the old terminology: the word 'polycystic' — meaning many cysts — implied that ovarian cysts were a defining feature of the condition, when in fact many women with the syndrome do not have cysts at all. Conversely, some women with ovarian cysts do not have the syndrome. The new name shifts the focus toward what researchers now understand to be the condition's true nature: a complex interplay of endocrine (hormonal) dysfunction and metabolic disruption.
The condition, which affects an estimated 8 to 13 per cent of women of reproductive age globally, is characterised by symptoms including irregular menstrual cycles, elevated androgen levels, insulin resistance, and fertility challenges. Under the old name, many women faced delayed or missed diagnoses, particularly those who did not present with the 'textbook' picture of ovarian cysts.
"The name was very inaccurate," health experts noted, as the syndrome's reach extends well beyond the ovaries and involves systemic hormonal and metabolic processes. The new name — polyendocrine metabolic ovarian syndrome — captures the multi-gland hormonal involvement ('polyendocrine'), the metabolic component, and retains the ovarian reference to preserve continuity for clinicians and patients familiar with the condition.
Proponents of the renaming argue it carries practical clinical benefits. A more accurate name is expected to guide general practitioners toward broader diagnostic criteria, reducing the number of women dismissed because they lack cysts on ultrasound. It may also encourage research funding and pharmaceutical development focused on the metabolic and endocrine dimensions of the condition.
The renaming also has implications for women outside the traditional reproductive-age bracket. Because PCOS — now PMOS — involves systemic metabolic effects including increased risk of type 2 diabetes, cardiovascular disease, and mental health conditions, the new framing may prompt clinicians to monitor and treat affected women across a wider range of ages and presentations.
While the new name has been broadly welcomed, transitions of this kind carry practical challenges. Medical coding systems, patient records, research literature, and public health resources will all require updating — a process that typically unfolds over years rather than months. Patient communities, many of which have built significant support networks under the PCOS banner, will also need time to adapt.
No dissenting voices from major medical bodies have been reported at this stage, though broader community and clinical feedback is likely to emerge as the new terminology enters everyday use.
Analysis
Why This Matters
- Millions of women worldwide with this condition — estimated at 8–13% of those of reproductive age — stand to benefit from faster, more accurate diagnoses if the new name guides clinicians away from the misleading 'cyst' framing.
- The shift in terminology signals a broader rethinking of the condition as a systemic metabolic and hormonal disorder, which could drive new research directions, treatment approaches, and funding priorities.
- For women who were previously dismissed or misdiagnosed because they lacked ovarian cysts, the renaming offers both clinical and psychological validation that their symptoms are real and recognised.
Background
Polycystic ovary syndrome was first described in the 1930s by American gynaecologists Irving Stein and Michael Leventhal, and has carried variants of the 'polycystic' label ever since. For decades, the presence of multiple follicles on the ovaries — visible on ultrasound and described colloquially as 'cysts' — was treated as the hallmark of the condition.
However, as diagnostic tools and hormonal research advanced through the latter decades of the 20th century, it became increasingly clear that the syndrome was far more heterogeneous than the name suggested. Many women meeting diagnostic criteria had no cysts, while ovarian cysts alone were insufficient for a diagnosis. Critics of the terminology grew louder through the 2000s and 2010s, with patient advocacy groups and endocrinologists pushing for a name that better reflected the condition's hormonal and metabolic complexity.
By the 2020s, international clinical guidelines — including those from the European Society of Human Reproduction and Embryology and the Androgen Excess and PCOS Society — had evolved significantly, broadening diagnostic criteria and emphasising metabolic health. The renaming to PMOS represents the formal culmination of this decades-long scientific and patient-driven reassessment.
Key Perspectives
Health experts and clinicians: Support the change as scientifically overdue. The new name is expected to improve diagnostic accuracy, reduce stigma around the 'cyst' association, and encourage a whole-body approach to managing the condition's metabolic and cardiovascular risks.
Patient advocates: Many women with the condition have long campaigned for a name change, arguing that 'polycystic' led to dismissal by doctors and confusion among patients themselves. The new name is widely seen as a validation of their experience and a step toward better care.
Critics and cautious observers: Some raise practical concerns about the disruption a name change causes — including updating medical records, clinical coding systems, research literature, and public awareness campaigns. There is also a risk that established patient communities, built around the 'PCOS' identity, may face confusion during the transition period.
What to Watch
- How quickly major health systems, including Australia's Medicare Benefits Schedule and international equivalents, update their diagnostic codes and clinical guidelines to reflect the new terminology.
- Whether the renaming translates into measurable improvements in diagnosis rates, particularly for women without ovarian cysts on ultrasound who have historically been turned away.
- The response from patient communities and support organisations that have operated under the PCOS banner — and whether they adopt PMOS branding or face challenges in the transition.